Becker's Healthcare May 10, 2022
Mackenzie Bean

Pfizer has agreed to acquire the migraine treatment maker Biohaven Pharmaceuticals for $11.6 billion, the drugmaker said May 10.

Four things to know:

1. Pfizer first invested in Biohaven last November, according to ABC News. The company will buy all remaining shares at $148.50 per share in cash.

2. Biohaven makes rimegepant, an FDA-approved...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours

Share This Article